Jonathan J. Darrow, S.J.D., J.D., M.B.A., LL.M.
Dr. Darrow joined the faculty of Harvard Medical School and the Program On Regulation, Therapeutics, And Law (PORTAL) in 2016, following service as Senior Law Clerk to a judge on the United States Court of Appeals for the Federal Circuit, the court that decides patent appeals involving pharmaceuticals, biologics, and medical devices. He holds degrees in biological sciences / genetics, law, and business from Cornell, Duke, and Boston College, respectively, as well as a research doctorate in pharmaceutical policy and intellectual property theory from Harvard, where he also completed the LL.M. program. He has been qualified as a patent attorney since 2002. After admission to the California bar, Dr. Darrow worked on pharmaceutical litigation matters at Wiley Rein & Fielding in Washington, DC, served on the business law faculties of several universities, and explored the relationship between innovation policy and global health during stints at the World Trade Organization, the World Health Organization, and the World Intellectual Property Organization.
He is a co-author of three textbooks, including Cyberlaw: Management & Entrepreneurship (2015) and The Legal and Ethical Environment of Business (2014). His scholarship on health policy and intellectual property has appeared in the British Medical Journal, the New England Journal of Medicine (on topics such as expedited FDA regulatory review and expanded access to investigational drugs); the Journal of Law, Medicine & Ethics; the Stanford Technology Law Review; the Yale Journal of Health Policy Law & Ethics, and the Harvard Journal of Law & Technology, among many others, and he has testified before a committee of the Massachusetts legislature on an emerging issue of law and technology.
He is a co-author of three textbooks, including Cyberlaw: Management & Entrepreneurship (2015) and The Legal and Ethical Environment of Business (2014). His scholarship on health policy and intellectual property has appeared in the British Medical Journal, the New England Journal of Medicine (on topics such as expedited FDA regulatory review and expanded access to investigational drugs); the Journal of Law, Medicine & Ethics; the Stanford Technology Law Review; the Yale Journal of Health Policy Law & Ethics, and the Harvard Journal of Law & Technology, among many others, and he has testified before a committee of the Massachusetts legislature on an emerging issue of law and technology.
